Continuous and intensified bioprocessing is attracting much attention from biopharmaceutical companies seeking to maximize the efficiency of their manufacturing assets. Continuous bioprocessing promises smaller facilities, reduced scale-up risk, more consistent product quality and higher throughputs. Biomanufacturers can gain a competitive advantage over their rivals by being able to reduce their cost of goods. How then should process development scientist and engineers approach the development of a continuous or intensified platform?
This webinar will provide practical advice for those trying to develop and implement continuous processes. It will explain the tools and techniques that can be used during process development and describe how process-scale equipment can be configured to allow effective and predictable scale-up.
The presenter will highlight emerging technologies for cell retention and describe the benefits and drawbacks of different configurations for continuous purification. Furthermore, the audience will learn the importance of having appropriate process analytical tools to control continuous bioprocesses. The key learning points will be illustrated with examples from industry.
Please register to reserve your spot for this exciting webinar and we look forward to welcoming you to our presentation.
Gerben Zijlstra
Platform Marketing Manager Continuous BioManufacturing
Dr. ir. Gerben Zijlstra received his Ph.D. from the University of Wageningen, The Netherlands. Following his Ph.D., Gerben joined DSM Biologics in Groningen The Netherlands, where he held various positions within the process development, cGMP manufacture, and engineering departments, with a focus on introducing new (platform) processes, new process equipment into the facility and tech transfer of commercial processes to other sites.
Gerben has been involved in the process development of several commercial Bio-therapeutics, as well as platform process development (e.g. PER.C6, CHO) and technology development projects. He was part of the team responsible for the introduction of disposable stirred tank bioreactors at DSM Biologics as early as 2006.
Gerben has worked extensively in the field of process intensification, integration and Continuous Biomanufacturing in animal cell culture. He is the first named inventor of the XD® (Concentrated Fed-Batch) technology, a highly intensified continuous cultivation mode in which cell densities of over 240 mln cells/mL and MAb titers over 27 g/L have been achieved. This technology was licensed to Amgen, amongst others, to become part of their Continuous Biomanufacturing platform toolkit.
He has furthermore contributed to the development, scale-up and tech transfer of Concentrated Fed-Batch technology to the Patheon Biologics Brisbane site for commercial scale manufacturing. This site received the 2014 ISPE facility of the year award for process innovations.
He worked as a Senior Consultant at Xendo BV in Leiden the Netherlands and was deeply involved in several Continuous BioManufacturing projects. Gerben is a regular speaker on international conferences on the topics of process intensification, process integration and continuous biomanufacturing.
- Developing continuous bioprocesses
- Configuring process-scale equipment for continuous bioprocessing
- Emerging cell retention technologies
- Role of PAT tools for continuous bioprocessing
- Process Development Scientists
- Process Development Managers
- Process Engineers
- Engineering Directors
